Clinical Trials Browser

OTHER × Endometrial Neoplasms × anlotinib × Clear all

NCT05550558 2022-09-28

CAN-RESPOND

Phase 2 Not yet recruiting

Endometrial Neoplasms

NCT04157491 2019-11-08

Anti-PD-1 Antibody Combined With Anlotinib in the Treatment of Endometrial Cancer

Phase 1/2 Unknown

Endometrial Neoplasms